Wells Fargo initiated coverage on Alkermes Plc with a new price target
$ALKS
Biotechnology: Pharmaceutical Preparations
Health Care
Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/3/2025 | $44.00 | Overweight | Wells Fargo |
| 7/15/2025 | $43.00 | Buy | Goldman |
| 6/17/2025 | $42.00 | Neutral → Buy | UBS |
| 5/28/2025 | $45.00 | Buy | Needham |
| 3/13/2025 | $40.00 | Sector Perform | RBC Capital Mkts |
| 3/4/2025 | $21.00 → $38.00 | Sell → Neutral | UBS |
| 2/11/2025 | $40.00 | Buy | Deutsche Bank |
| 11/5/2024 | $25.00 → $36.00 | Hold → Buy | Stifel |
Wells Fargo initiated coverage of Alkermes Plc with a rating of Overweight and set a new price target of $44.00
Goldman initiated coverage of Alkermes Plc with a rating of Buy and set a new price target of $43.00
UBS upgraded Alkermes Plc from Neutral to Buy and set a new price target of $42.00
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
4 - Alkermes plc. (0001520262) (Issuer)
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly ALKS 2680, is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment f
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company. Alixorexton, formerly referred to as ALKS 2680, is the c
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive
SCHEDULE 13G/A - Alkermes plc. (0001520262) (Subject)
S-8 - Alkermes plc. (0001520262) (Filer)
10-Q - Alkermes plc. (0001520262) (Filer)
– First Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Impact on Wakefulness, Cognition and Fatigue with Once-Daily Dosing Across a Range of Doses – – Alixorexton Was Generally Well Tolerated at All Doses Tested – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Sept. 7, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced detailed positive results from the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly ALKS 2680, is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2 development as a once-daily treatment f
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition – – Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET – DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company. Alixorexton, formerly referred to as ALKS 2680, is the c
— Second Quarter Revenues of $390.7 Million — — GAAP Net Income of $87.1 Million and Diluted GAAP Earnings per Share of $0.52 — — Company Reiterates 2025 Financial Expectations — — Alkermes to Present Detailed Vibrance-1 Results at Upcoming World Sleep Congress — DUBLIN, July 29, 2025 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today reported financial results for the second quarter of 2025. "Our second quarter results reflect strong performance across all three of our proprietary products and robust profitability and cash flow generation," said Richard Pops, Chief Executive Officer of Alkermes. "Against the backdrop of solid financial performance, the recently announced positive
SC 13G - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
SC 13G/A - Alkermes plc. (0001520262) (Subject)
DUBLIN, March 7, 2024 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of a new independent director, Nancy S. Lurker, to the company's Board of Directors (the Board). Ms. Lurker is a seasoned healthcare executive and experienced board member who brings decades of pharmaceutical and biotechnology industry leadership experience and strong commercial expertise, including a track record of successful U.S. and global pharmaceutical product launches. "Nancy brings to the Board deep biopharmaceutical industry experience spanning executive leadership, govern
NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t
— Dr. Loew to Assume New Leadership Role Upon Completion of the Planned Separation of Alkermes' Oncology Business — — Planned Separation Remains on Track to be Completed in Second Half of 2023 — DUBLIN, June 1, 2023 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that Caroline J. Loew, Ph.D., has been appointed as the chief executive officer designate of Mural Oncology plc (Mural Oncology), the new independent public company to be established upon the planned separation of Alkermes' oncology business. Dr. Loew will join Alkermes in June as a strategic advisor and transition to CEO of Mural Oncology upon completion of the separation. "Dr. Loew's deep knowledge of the oncology fi